Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)

October 2019

Questions will pop up about the safety of Janus kinase (JAK) inhibitors...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of JAK inhibitors for rheumatoid arthritis and other autoimmune diseases...because they're oral.

But these specialty meds may fly under your radar if patients don't fill them at your pharmacy.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza Share the Latest Advice About 2019-2020 Influenza Immunizations
E-Cigarettes Emphasize Risks of Vaping and Help Kids and Teens Stop
Medicare Be Familiar With Changes Coming to Medicare Part D in 2020
Anticoagulants Help Manage Direct Oral Anticoagulants Around Surgery
Pediatrics Weigh Options for Managing Type 2 Diabetes in Kids
Contraceptives Don't Jump to the New Progestin-Only Oral Contraceptive, Slynd (Drospirenone)
Pharmacy Practice Demystify the Ins and Outs of Compression Stockings
Vaccines Know When to Discuss HPV Vaccination With Adults Over Age 26
Antibiotics Save the Antibiotic Xenleta as a Last Resort
Immunosuppressives Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)
IBS Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation